Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (2.9), the stock would be worth $1.86 (47% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.4 | $3.48 |
0%
|
| 3-Year Average | 2.9 | $1.86 |
-47%
|
| 5-Year Average | 3.2 | $2.07 |
-41%
|
| Industry Average | 5.6 | $3.62 |
+4%
|
| Country Average | 3 | $1.98 |
-43%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$531.4m
|
/ |
Jan 2026
$185.7m
|
= |
|
|
$531.4m
|
/ |
Dec 2026
$209m
|
= |
|
|
$531.4m
|
/ |
Dec 2027
$225.5m
|
= |
|
|
$531.4m
|
/ |
Dec 2028
$241.6m
|
= |
|
|
$531.4m
|
/ |
Dec 2029
$258m
|
= |
|
|
$531.4m
|
/ |
Dec 2030
$278.9m
|
= |
|
|
$531.4m
|
/ |
Dec 2031
$338.3m
|
= |
|
|
$531.4m
|
/ |
Dec 2032
$380.6m
|
= |
|
|
$531.4m
|
/ |
Dec 2033
$428.2m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
|
890.9m USD | 5.4 | -3.9 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 328.4 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.3B USD | 4.6 | 25.3 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.5B USD | 5.6 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 17.9 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 6.3 | 16.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.1B CHF | 5.5 | -118.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD | 4.7 | 24.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
28.7B USD | 9.2 | 44.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.6B USD | 2.4 | 19.6 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.2B USD | 6.8 | 29 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
Maravai LifeSciences Holdings Inc
Glance View
Maravai LifeSciences Holdings Inc. operates in the niche yet burgeoning market of life sciences, where its business revolves around the creation and supply of essential products and services for biotechnology workflows. Founded in 2014 and headquartered in San Diego, California, Maravai specializes in providing key components for the development of diagnostics and therapeutics. A significant portion of its revenue is driven by its business unit, TriLink BioTechnologies, which is instrumental in the synthesis of nucleic acids, notably mRNA and modified nucleotides – critical for the development of mRNA vaccines like those used in combating COVID-19. This has positioned Maravai as a crucial player during the pandemic, spotlighting its capability to provide high-quality inputs that support leading-edge scientific innovations. The company’s financial engine is powered by its diversified product offerings across three main segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. Beyond just supplying raw materials, Maravai elevates its contributions by ensuring these components meet rigorous quality standards necessary for clinical applications. The robust demand for both biopharmaceutical innovation and bioprotection has allowed Maravai to capitalize on trends such as personalized medicine and gene therapy. By navigating these influential currents in the biotechnology space, Maravai LifeSciences not only gains from direct sales of its products but also cultivates long-standing partnerships across pharmaceutical and research organizations, underscoring its integral role in the ongoing evolution of life sciences.
